Skip to main
HUM
HUM logo

Humana (HUM) Stock Forecast & Price Target

Humana (HUM) Analyst Ratings

Based on 37 analyst ratings
Buy
Strong Buy 19%
Buy 27%
Hold 51%
Sell 3%
Strong Sell 0%

Bulls say

Humana's positive outlook is bolstered by stable cost trends and the potential for significant improvement in adjusted EPS following a successful appeal concerning star ratings for several contracts. The company expects stronger revenue performance and is benefiting from strategic actions in Medicare Advantage pricing, as well as incremental investments geared towards enhancing clinical excellence and operational improvements. Additionally, the firm's solid competitive positioning within the Medicare Advantage landscape, supported by its above-industry star rating profile, positions it favorably against ongoing regulatory and reimbursement changes.

Bears say

The financial outlook for Humana is negatively impacted by persistent margin pressures and a significant miss regarding Stars ratings, which raises concerns about the company's future performance and operational efficiency. Current guidance for 2025 suggests flat earnings per share (EPS), indicating stagnation, while projected earnings could be further pressured by the anticipated turnaround timeline for the Medicare Advantage book extending to 2028, rather than 2027. These factors contribute to a cautious stance regarding Humana's stock, as the company faces elevated investment needs and ongoing utilization pressures, raising doubts about its ability to achieve targeted margins in the near term.

Humana (HUM) has been analyzed by 37 analysts, with a consensus rating of Buy. 19% of analysts recommend a Strong Buy, 27% recommend Buy, 51% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humana (HUM) Forecast

Analysts have given Humana (HUM) a Buy based on their latest research and market trends.

According to 37 analysts, Humana (HUM) has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $318.30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $318.30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humana (HUM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.